Myriad Genetics (NASDAQ:MYGN) Stock

MYRIAD GENETICS INC

Myriad Genetics

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Myriad Genetics Inc

In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.1, accompanied by a high estimate of $29.00 and a low estimate of $11.00. Highlighting a 14.76% decrease, the current average has fallen from the previous average price target of $20.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544820_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Myriad Genetics</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Breaking Down Myriad Genetics's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.12%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Myriad Genetics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MYGN

10 Analysts Assess Myriad Genetics: What You Need To Know

Scotiabank analyst Sung Ji Nam maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Sector Outperform and lowers the price target from $24 to $20.

News

Price Target

Scotiabank Maintains Sector Outperform on Myriad Genetics, Lowers Price Target to $20

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday.
Shares of Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) fell sharply in today's <a href="https://www.benzinga.com/quote/EE">pre-market trading</a>.
Excelerate Energy announced the pricing of upsized public offering of class A common stock.
Excelerate Energy shares dipped 6.8% to $26.74 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) shares dipped 13.1% to $7.71 in today's pre-market trading.</li>
<li>Sunstone Hotel Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) declined 9.7% to $8.50 in pre-market trading. Sunstone Hotel Investors will report financial results for the first quarter 2025 on Tuesday, May 6.</li>
<li>Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) shares slipped 8.9% to $7.20 in pre-market trading after falling over 3% on Monday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) shares fell 8% to $10.24 in pre-market trading.</li>
<li>Target Hospitality Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) dipped 5.5% to $6.22 in pre-market trading.</li>
<li>Alumis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) declined 5.5% to $5.80 in pre-market trading.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) declined 4.7% to $3.88 in pre-market trading.</li>
<li>Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) declined 4.6% to $6.30 in pre-market trading.</li>
<li>Innoviva, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVA#NASDAQ">INVA</a>) fell 3.4% to $17.52 in pre-market trading.</li>
<li>MediaAlpha, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) declined 3% to $8.97 in pre-market trading. MediaAlpha named Bradley Hunt to Board of Directors.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALMS

INVA

KURA

ZBIO

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/25/03/44572437/calvin-klein-parent-pvh-shares-climb-on-strong-q4-fy25-eps-guidance-above-estimates">better-than-expected fourth-quarter financial results.</a>
Calvin Klein and Tommy Hilfiger parent company PVH reported quarterly earnings of $3.27 per share, which beat the analyst consensus estimate of $3.21. Quarterly revenue came in at $2.37 billion, which beat the analyst consensus estimate of $2.33 billion.
PVH shares jumped 15.2% to $74.50 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) gained 146.8% to $0.89 in pre-market trading after falling around 7% on Monday.</li>
<li>bioAffinity Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) rose 99.1% to $0.5176 in pre-market trading after the company reported a year-over-year increase in FY24 financial results.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) rose 46.6% to $68.99 in pre-market trading following strong FY sales results.</li>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 30% to $1.52 in pre-market trading after reporting fourth-quarter results.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) surged 28.5% to $1.00 in pre-market trading following a 9% decline on Monday.</li>
<li>Cloudastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) rose 25% to $5.55 in pre-market trading after reporting 2024 year-end results.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) gained 23.6% to $103.19 in pre-market after jumping 735% on Monday.</li>
<li>ON24, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) gained 14.2% to $5.94 in pre-market trading.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) gained 5.7% to $54.45 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cambium Networks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares fell 50.3% to $0.3490 in pre-market trading after the company announced that it will delay Form 10-K filing for fiscal year 2024.</li>
<li>1stdibs.Com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) fell 27% to $2.22 in pre-market trading.</li>
<li>Foghorn Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) declined 19.2% to $2.95 in pre-market trading.</li>
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) fell 18.5% to $0.52 in pre-market trading after dipping over 28% on Monday.</li>
<li>Lucas GC Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) dipped 18.2% to $0.40 in pre-market trading.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) fell 13.1% to $7.71 in today's pre-market trading.</li>
<li>Sunstone Hotel Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHO#NYSE">SHO</a>) fell 9.7% to $8.50 in pre-market trading. Sunstone Hotel Investors will report financial results for the first quarter 2025 on Tuesday, May 6.</li>
<li>Zenas BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) shares tumbled 8.9% to $7.20 in pre-market trading after falling over 3% on Monday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) shares dipped 8% to $10.24 in pre-market trading.</li>
<li>Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) shares fell 6.8% to $26.74 in pre-market trading. Excelerate Energy announced the pricing of upsized public offering of class A common stock.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a> </li>
</ul>
Image via Shutterstock

BIAF

CMBM

CSAI

DIBS

FHTX

LGCL

MVST

NMAX

NUTX

ONTF

PRGS

RSLS

SLNH

TNMG

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Health Care

General

VCYT

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Dave Weiner upgraded the rating for Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Neutral to Overweight and raised the price target from $11.5 to $12.5. Myriad Genetics shares closed at $10.25 on Tuesday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>CL King analyst Andrew Wolf upgraded the rating for United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) from Neutral to Buy and announced a $33 price target. United Natural Foods shares closed at $24.57 on Tuesday. <a href="https://www.benzinga.com/quote/UNFI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Ryan Macwilliams upgraded HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) from Equal-Weight to Overweight and maintained the price target of $815. HubSpot shares closed at $590.67 on Tuesday. <a href="https://www.benzinga.com/quote/HUBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine upgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Hold to Buy and maintained the price target of $110. Crocs shares closed at $98.32 on Tuesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) from Sector Weight to Overweight and announced a $340 price target. Eaton shares closed at $282.31 on Tuesday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HUBS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-1024x582.png" alt="" class="wp-image-821390" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12124655/image-86.png 1073w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

CROX

HUBS

UNFI

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

WIIM

Myriad Genetics shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $11.5 to $12.5.

Piper Sandler analyst Dave Weiner upgrades Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Neutral to Overweight and raises the price target from $11.5 to $12.5.

Piper Sandler Upgrades Myriad Genetics to Overweight, Raises Price Target to $12.5

Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $14 to $11.5.

Piper Sandler Maintains Neutral on Myriad Genetics, Lowers Price Target to $11.5

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.9, accompanied by a high estimate of $29.00 and a low estimate of $11.00. Observing a downward trend, the current average is 18.64% lower than the prior average price target of $22.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741028464_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Myriad Genetics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Myriad Genetics faced challenges, resulting in a decline of approximately -1.27% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -20.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.93% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio surpasses industry norms, standing at 0.2. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Myriad Genetics's Future

B of A Securities analyst Derik De Bruin maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Underperform and lowers the price target from $13 to $11.

B of A Securities Maintains Underperform on Myriad Genetics, Lowers Price Target to $11

Myriad Genetics shares are trading lower following a Q4 revenue miss and FY25 revenue guidance below estimates. The stock may also be trading on weakness after it announced it will face cost restructuring following UnitedHealthcare's decision to end Genesight coverage. Additionally, UBS and Raymond James cut their respective price targets on the stock.

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) said Unitedhealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics&#8217; GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43925676/myriad-genetics-reports-fourth-quarter-and-full-year-2024-financial-results-full-year-2024-revenue" rel="noreferrer noopener">in the first half of 2025</a>.
In 2024, Myriad Genetics earned about $45 million from GeneSight testing through UnitedHealthcare, with $40 million from commercial plans and $5 million from managed Medicaid plans.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses</a>
While Myriad Genetics continues to pursue a resolution with UnitedHealthcare that allows its commercial and managed Medicaid enrollees to continue accessing the GeneSight test, there is no guarantee that these efforts will succeed. Accordingly, Myriad has streamlined operations and cost structure.
Myriad Genetics also reported:
<ul>
<li>Fourth-quarter adjusted EPS of 3 cents, down from 4 cents a year ago, in line with the consensus.</li>
<li>Fourth-quarter sales of $210.6 million — up 7% year over year, missing the consensus of $211.62 million.</li>
<li>The Oncology business delivered revenue of $82.8 million in the fourth quarter of 2024. </li>
<li>Hereditary cancer testing revenue in Oncology grew 8% year-over-year.</li>
<li>Women's Health business delivered revenue of $87.2 million, and prenatal testing revenue grew 12% year-over-year.</li>
</ul>
Guidance: Myriad Genetics reaffirms 2025 adjusted EPS guidance of 7-11 cents compared to the consensus of 6 cents.
The company expects sales of $840 million-$860 million versus a consensus of $866.2 million.
CEO Change: Myriad Genetics appointed Sam Raha, the company&#8217;s current Chief Operating Officer, as President, CEO, and board member, <a href="https://www.benzinga.com/pressreleases/25/02/g43925648/myriad-genetics-announces-senior-leadership-transition" target="_blank" rel="noreferrer noopener">effective April 30</a>.
Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey &amp; Company.
Analyst Reactions:
<ul>
<li>JPMorgan writes that the fourth quarter miss was driven by softer volumes due to the focus on the launch of Prequel at 8 weeks gestational age and slower order activity among new EMR accounts.</li>
<li>JPMorgan analyst Rachel Vatnsda writes that while the company&#8217;s progress on its recovery plan is promising, there is uncertainty about its long-term growth strategy beyond selling assets. Therefore, JP Morgan <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">maintains the Underweight rating</a>.</li>
<li>UBS analyst Lu Li maintains Myriad Genetics with a Neutral and lowers the price target from $18 to $16.</li>
</ul>
Price Action: Myriad Genetics stock is down 14.2% at $11.83 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43943266/diagnostic-company-veracyte-weighs-sale-for-french-subsidiary-analyst-says-walking-away-is-a-long-term-positive" target="_blank" rel="noreferrer noopener">Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says &#8216;Walking Away&#8217; Is A Long-Term Positive</a></li>
</ul>

Earnings

Guidance

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

Raymond James analyst Andrew Cooper reiterates Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Outperform and lowers the price target from $27 to $19.

Reiteration

Raymond James Reiterates Outperform on Myriad Genetics, Lowers Price Target to $19

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $18 to $16.

UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $16

Myriad Genetics shares are trading lower after the company reported worse-than-expected Q4 revenue results and issued FY25 revenue guidance below estimates.

<a href="https://www.globenewswire.com/Tracker?data=WYdZcKsRw2ADAc9rIfTbKJfEAaKTqbkWJV2YNWjMI1fvP-D1aQj6cdmnrDpnvI9cBOKrX-cUCsyJX1YzQTowGg==">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey &amp; Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year.

Management

Myriad Genetics Appoints Sam Raha, The Company's Current COO As President And CEO, Effective April 30, 2025

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) affirms FY2025 Adj EPS guidance from $0.07-$0.11 to $0.07-$0.11 vs $0.06 analyst estimate. Affirms FY2025 sales outlook from $840.00 million-$860.00 million to $840.00 million-$860.00 million vs $866.15 million estimate.

Myriad Genetics Affirms FY2025 Adj EPS Guidance of $0.07-$0.11 vs $0.06 Est; Affirms FY2025 Sales Guidance of $840.00M-$860.00M vs $866.15M Est

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.03 per share which met the analyst consensus estimate. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $210.60 million which missed the analyst consensus estimate of $211.62 million by 0.48 percent. This is a 7.12 percent increase over sales of $196.60 million the same period last year.

Earnings Misses

Myriad Genetics Q4 Adj $0.03, Inline, Sales $210.60M Miss $211.62M Estimate

Biotech

Myriad Genetics Enters Collaboration With PATHOMIQ For Exclusive US License Of PATHOMIQ_PRAD AI Technology Platform For Prostate Cancer

Press Releases

Biote Announces CEO Retirement and Succession Plan

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

Legal

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test

Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

Myriad Genetics Included in Forbes America's Best Employers 2025 List

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Myriad Genetics Announces Senior Leadership Transition

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Comments

Myriad Genetics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL